

# HSCT - Minimum Essential Data - A FOLLOW UP REPORT - ANNUAL

## Disease

PRIMARY DISEASE DIAGNOSIS.....

## Centre Identification

EBMT Code (CIC): ..... Contact person: .....  
Hospital: ..... Unit: ..... Email: .....

## Patient Data

Date of this report: .....  
yyyy - mm - dd

Patient following national / international study / trial:  No  Yes  Unknown

Name of study / trial .....

Hospital Unique Patient Number/ Code: .....

(Compulsory, registrations will not be accepted without this item)

Initials: ..... (first name(s) \_ family name(s))

Date of birth .....  
yyyy - mm - dd

Sex  Male  Female

(at birth)

Date of the most recent transplant before this follow up: .....  
yyyy - mm - dd

## Date of Last Contact

Date of last follow up or death: .....  
yyyy - mm - dd

## Best response after HSCT (CLL & Myeloma only)

### Best disease status (response) after transplant

(prior to any treatment modification in response to a post HSCT disease assessment)

- Continued complete remission (CCR)
- CR achieved: Date achieved : .....  
yyyy - mm - dd
- Never in CR: Date assessed: .....  
yyyy - mm - dd
- Previously reported

## Secondary Malignancy

**Did a secondary malignancy, lymphoproliferative or myeloproliferative disorder occur?**

No  Yes:

Date of diagnosis: .....  
yyyy - mm - dd

Diagnosis: .....

THE PATIENT HAS RECEIVED AN ALLOGRAFT PRIOR TO THE DIAGNOSIS OF ACUTE LEUKAEMIA, ANSWER THE FOLLOWING QUESTION

Is this secondary malignancy a donor cell leukaemia?  No  Yes  Not Applicable

## Additional Disease Treatment including Cell Therapy

**Was additional treatment given for the disease indication for transplant?**

No  
 Yes: Start date of the additional treatment since last report .....  
 yyyy - mm - dd

### -Cell therapy

Did the disease treatment include additional cell infusions ***(excluding a new HSCT)***

No  
 Yes: Is this cell infusion an allogeneic boost?  No  Yes:

*An allo boost is an infusion of cells from the same donor without conditioning, with no evidence of graft rejection.*

Is this cell infusion an autologous boost?  No  Yes:

➡ **If cell infusion is not a boost, please attach the Cell Infusion (CI) sheet on the last page, completing as many sections as episodes of cell infusion that took place during this interval, then continue below**

### -Chemo / radiotherapy

**Additional disease treatment given excluding cell infusion?**

No  
 Yes:  Prophylaxis / preemptive/ preventive *(planned before the transplant took place)*  
 For relapse / progression or persistent disease *(not planned)*

Date started .....  
 yyyy - mm - dd

Chemo/drug

No Tick here if continuous from last follow up report

Yes:

<input type="checkbox"/> Imatinib mesylate (Gleevec, Glivec)	<input type="checkbox"/>
<input type="checkbox"/> Dasatinib (Sprycel)	<input type="checkbox"/>
<input type="checkbox"/> Nilotinib (Tasigna)	<input type="checkbox"/>
<input type="checkbox"/> Bortezomib (Velcade)	<input type="checkbox"/>
<input type="checkbox"/> Lenalidomide (Revlimid)	<input type="checkbox"/>
<input type="checkbox"/> Rituximab (Rituxan, mabthera)	<input type="checkbox"/>
<input type="checkbox"/> Velafermin (FGF)	<input type="checkbox"/>
<input type="checkbox"/> Kepivance (KGF, palifermin)	<input type="checkbox"/>
<input type="checkbox"/> Thalidomide	<input type="checkbox"/>
<input type="checkbox"/> Eculizumab (Soliris)	<input type="checkbox"/>
<input type="checkbox"/> Other drug/chemotherapy, specify .....	<input type="checkbox"/>

Intrathecal:  No  Yes

Radiotherapy  No  Yes  Unknown

## Relapse or Progression after HSCT

**First Relapse or Progression after HSCT** *(detected by any method)*

No:  
 Yes: Date first seen .....  
 yyyy - mm - dd  
 Continuous progression since HSCT

## Relapse of Leukaemias

If Yes or Continuous **and** diagnosis is acute or chronic leukaemia, fill in the section below:

### Method of detection of the first relapse or progression after HSCT

Fill in only for acute and chronic **leukaemias**

Relapse/progression detected by **clinical/haematological** method:

- No: Date assessed .....
- Yes: Date first seen .....
- Not evaluated .....  
yyyy - mm - dd

Relapse/progression detected by **cytogenetic** method:

- No: Date assessed .....
- Yes: Date first seen .....
- Not evaluated .....  
yyyy - mm - dd

Relapse/progression detected by **molecular** method:

- No: Date assessed .....
- Yes: Date first seen .....
- Not evaluated .....  
yyyy - mm - dd

## Last disease status – All diseases

### Disease status when the patient was last assessed? (or date of death)

(record the most recent status and date for each method, depending on the disease)

Was disease detected by **clinical/haematological** method when the patient was last assessed or date of death?

- No  Yes

Last date assessed .....  
yyyy - mm - dd

- Not evaluated since HSCT was done

## Last disease assessment - Leukaemias

Was disease detected by **cytogenetic/FISH** method when the patient was last assessed or date of death?

Fill in only for acute and chronic **leukaemias**

- No  Yes: Was the presence of the disease considered relapse/progression since HSCT?  No  Yes

Last date assessed .....  
yyyy - mm - dd

- Not evaluated during this period

Was disease detected by **molecular** method when the patient was last assessed or date of death?

Fill in only for acute and chronic **leukaemias**

- No  Yes: Was the presence of the disease considered relapse/progression since HSCT?  No  Yes

Last date assessed .....  
yyyy - mm - dd

- Not evaluated during this period

## Pregnancy after HSCT

Has patient or partner become pregnant after this transplant?

- No  
 Yes: Did the pregnancy result in a live birth?     No     Yes:     Unknown  
 Unknown

## Survival Status

- Alive     Dead

Check here if patient lost to follow up   

**Main Cause of Death** (check only one main cause):

- Relapse or Progression/Persistent disease  
 Secondary malignancy  
 HSCT Related Cause  
 Unknown  
 Other: \_\_\_\_\_

**Contributory Cause of Death** (check as many as appropriate):

- GVHD  
 Interstitial pneumonitis  
 Pulmonary toxicity  
 Infection:  
      bacterial  
      viral  
      Fungal  
      parasitic  
      Unknown  
 Rejection/Poor graft function  
 History of severe Veno occlusive disorder (VOD)  
 Haemorrhage  
 Cardiac toxicity  
 Central nervous system (CNS) toxicity  
 Gastrointestinal (GI) toxicity  
 Skin toxicity  
 Renal failure  
 Multiple organ failure  
 Other: \_\_\_\_\_

# HSCT - Minimum Essential Data - A FOLLOW UP REPORT - ANNUAL

## CELL INFUSION (CI) SHEET

### CELL INFUSION

Date of first infusion: .....  
yyyy - mm - dd

Disease status before this CI  CR  Not in CR  Not evaluated

Cell infusion (CI) regimen (not HSCT or autologous stem cell re-infusion)

Source of cell(s):  Allo  Auto  
(check all that apply)

Type of cell(s): (check all that apply)

- Lymphocyte (DLI)     Mesenchymal     Fibroblasts     Dendritic cells
- NK cells     Regulatory T-cells     Gamma/delta cells     Other, specify \_\_\_\_\_

Chronological number of CI for this patient \_\_\_\_\_

- Indication:  Planned/protocol     Prophylactic     Mixed chimaerism
- (check all that apply)  Loss/decreased chimaerism     Treatment of aGvHD     Treatment of cGvHD
- Treatment for disease     Treatment PTLD, EBV lymphoma
- Treatment viral infection     Other, specify: \_\_\_\_\_

Number of infusions within 10 weeks ..... (count only infusions that are part of same regimen and given for the same indication)

Acute Graft Versus Host Disease (after this infusion but before any further infusion / transplant):

Maximum Grade:  0 (none)     1     2     3     4     Present but grade unknown

### CELL INFUSION

Date of first infusion: .....  
yyyy - mm - dd

Disease status before this CI  CR  Not in CR  Not evaluated

Cell infusion (CI) regimen (not HSCT or autologous stem cell re-infusion)

Source of cell(s):  Allo  Auto  
(check all that apply)

Type of cell(s): (check all that apply)

- Lymphocyte (DLI)     Mesenchymal     Fibroblasts     Dendritic cells
- NK cells     Regulatory T-cells     Gamma/delta cells     Other, specify \_\_\_\_\_

Chronological number of CI for this patient \_\_\_\_\_

- Indication:  Planned     Prophylactic     Mixed chimaerism
- (check all that apply)  Loss/decreased chimaerism     Treatment of aGvHD     Treatment of cGvHD
- Treatment for disease     Treatment PTLD, EBV lymphoma
- Treatment viral infection     Other, specify: \_\_\_\_\_

Number of infusions within 10 weeks ..... (count only infusions that are part of same regimen and given for the same indication)

Acute Graft Versus Host Disease (after this infusion but before any further infusion / transplant):

Maximum Grade:  0 (none)     1     2     3     4     Present but grade unknown